Brief: 3D Medicines Says 3D185 Granted Orphan-Drug Designation By U.S. FDA
13/01/2023 14:40
Jan 13 (Reuters) - 3D Medicines Inc 1244.HK :
* 3D185 GRANTED ORPHAN-DRUG DESIGNATION BY U.S. FDA- FOR
TREATMENT
OF GASTRIC CANCER AND- GASTRO-ESOPHAGEAL JUNCTION CANCER
Further company coverage: 1244.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 3D Medicines
See all newsBrief: 3D Medicines Inc Says Envafolimab Supplemental Application Accepted By NMPA
Brief: 3D Medicines Inc Says Zhang Jing Resigns As CFO
Brief: 3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted
Brief: 3D Medicines Says Envafoimab Granted Orphan Drug Designation
Brief: 3D Medicines Inc Enters Strategic Agreement With Catug Biotechnology